Trials / Completed
CompletedNCT01084330
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
A Randomized, Open-label, Multi-center Phase II Study to Compare AUY922 With Docetaxel or Irinotecan in Adult Patients With Advanced Gastric Cancer, Who Have Progressed After One Line of Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AUY922 | 70mg/m2 |
| DRUG | Docetaxel | Docetaxel 75mg/m2 |
| DRUG | Irinotecan | Iriniotecan 350mg/m2 |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2012-05-01
- Completion
- 2012-05-01
- First posted
- 2010-03-10
- Last updated
- 2020-12-10
Locations
36 sites across 14 countries: United States, Australia, Canada, France, Germany, Italy, Netherlands, Russia, Singapore, South Korea, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01084330. Inclusion in this directory is not an endorsement.